Antithrombotic Therapy

Case Report: 62-year-old man with shortness of breath after taking antibiotic

January 15, 2020

A 62-year-old male with history of coronary artery disease and prior coronary bypass surgery eight years ago presents to the emergency department after having two days of intermittent shortness of breath since starting cephalexin (Keflex) for a skin infection three days ago. He states the shortness of breath seems to get worse about an hour after taking cephalexin (Keflex). Can you diagnose this patient?

Antiplatelet and Anticoagulant Therapy Varies Greatly After TAVR

December 09, 2019

A review published in JAMA Cardiology reports that while patients with severe aortic stenosis are increasingly undergoing transcatheter aortic valve replacement (TAVR) procedures in place of surgery, there is little evidence on how best to utilize adjunctive antithrombotic therapy after the treatment.

6 Findings on CVD Aspirin Use That Should Be on Your Radar

December 09, 2019

Earlier this year, the American College of Cardiology and the American Heart Association updated treatment guidelines for the primary prevention of cardiovascular disease. They discourage the use of aspirin for this purpose, but in high-risk patients who are not at risk of bleeding, aspirin continues to be part of combination treatment regimens. In this slideshow, we highlight recent findings on aspirin use.

Antiplatelet Therapy Resistance in Diabetes Due to Low Vitamin D

August 16, 2019

Severe vitamin D deficiency in people with diabetes treated with dual antiplatelet therapy (DAPT) after an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) is associated with high residual platelet reactivity in patients taking the adenosine-diphosphate (ADP) antagonists ticagrelor or prasugrel, according to an exploratory study epublished on June 7 by Vascular Pharmacology.

Antithrombotic Therapy for the Prevention of Secondary Coronary Artery Disease

August 16, 2019

The advent of newer antiplatelet agents and oral anticoagulants has allowed new regimens for secondary prevention of coronary artery disease. When combination therapy is needed, the bleeding risk is particularly pronounced, and the benefits and risks must be balanced for individual patients.

Optimal Treatment for Complex Afib Cases Excludes Aspirin

March 19, 2019

Atrial fibrillation patients at risk for acute coronary syndrome, stroke and blood clots have better outcomes with an antithrombotic regimen of apixaban without aspirin, researchers report.

Aspirin, Clopidogrel, DOAC, Warfarin: What Combination after PCI in Patients with AF?

September 20, 2017

Quick Quiz: Which antiplatelet/antithrombin combination provides greatest efficacy with least risk for bleeding?